NasdaqCM - Nasdaq Real Time Price USD

Cardio Diagnostics Holdings, Inc. (CDIO)

4.3804
+0.5404
+(14.07%)
As of 1:08:45 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, CEO & Director 311k -- 1989
Ms. Elisa Michael Luqman Esq., J.D., M.B.A. CFO & Principal Accounting Officer 275k -- 1964
Mr. Timur Dogan Ph.D. Chief Technology Officer 259.17k -- 1989
Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer & Director -- -- 1962
Ms. Khullani Abdullahi J.D. Vice President of Revenue & Strategy -- -- 1984

Cardio Diagnostics Holdings, Inc.

311 West Superior Street
Suite 444
Chicago, IL 60654
United States
855 226 9991 https://cdio.ai
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
13

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Corporate Governance

Cardio Diagnostics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 12, 2025 at 8:00 PM UTC - August 16, 2025 at 8:00 PM UTC

Cardio Diagnostics Holdings, Inc. Earnings Date

Recent Events

May 15, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 8, 2025 at 12:00 AM UTC

S-8: Offering Registrations

March 20, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 13, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 7, 2025 at 12:00 AM UTC

S-3: Offering Registrations

December 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 2, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

November 22, 2024 at 12:00 AM UTC

S-1: Offering Registrations

Related Tickers